Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Corvas completes enrollment for rNAPc2 phase II study

June 26, 2000

Boehringer Ingelheim claims thrombin inhibitor series

June 23, 2000

Antiplatelet compounds in early development at Welfide superior to cilostazol in activity, safety

June 23, 2000

TP receptor antagonist S-18886 shows broad-spectrum antiplatelet effects

June 22, 2000

LY-203638 effective in patients with HIT

June 21, 2000

Thrombotic thrombocytopenic purpura associated with clopidogrel

June 16, 2000

Thrombin inhibitors from Merck reported to have nanomolar inhibitory activity

June 14, 2000

Integrin-inhibitory chromenone and chromanone derivatives synthesized at Merck

June 14, 2000

Anticoagulant and antithrombotic effects of PD-200022 reported at ASBMB/ASPET

June 14, 2000

GenStar's new Ad vector for hemophilia A proves safe and effective in murine model

June 13, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...